Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Food Effect on PK of LPM3770164 in Healthy Subjects
NCT06474650Phase 1Completed
- Sponsor
- Luye Pharma Group
- Start
- Jul 2024
- Primary completion
- Sep 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of LPM3770164 in Huntington disease (HD) and tardive dyskinesia (TD) (2 arms), sponsored by Luye Pharma Group. Primary endpoints: Peak Plasma Concentration, Area Under the Curve from time 0 to the last measurable concentration and 1 more. Started Jul 2024; status: completed.
02
Drugs
LPM3770164
03
Conditions
Huntington disease (HD)tardive dyskinesia (TD)
Beyond the preview
Go deeper on NCT06474650.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06474650.